Does TILDRAKIZUMAB Cause Condition aggravated? 25 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 25 reports of Condition aggravated have been filed in association with TILDRAKIZUMAB (ILUMYA). This represents 2.9% of all adverse event reports for TILDRAKIZUMAB.
25
Reports of Condition aggravated with TILDRAKIZUMAB
2.9%
of all TILDRAKIZUMAB reports
0
Deaths
5
Hospitalizations
How Dangerous Is Condition aggravated From TILDRAKIZUMAB?
Of the 25 reports, 5 (20.0%) required hospitalization, and 5 (20.0%) were considered life-threatening.
Is Condition aggravated Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TILDRAKIZUMAB. However, 25 reports have been filed with the FAERS database.
What Other Side Effects Does TILDRAKIZUMAB Cause?
Product dose omission issue (53)
Death (50)
Drug ineffective (50)
Psoriasis (37)
Urinary tract infection (36)
Pneumonia (33)
Off label use (27)
Covid-19 (25)
Inappropriate schedule of product administration (22)
Cerebrovascular accident (20)
What Other Drugs Cause Condition aggravated?
TOFACITINIB (16,925)
INFLIXIMAB (16,616)
DUPILUMAB (16,459)
ETANERCEPT (15,897)
METHOTREXATE (14,938)
ADALIMUMAB (13,527)
PREDNISONE (10,751)
INFLIXIMAB-DYYB (10,275)
HYDROXYCHLOROQUINE (8,848)
RITUXIMAB (8,627)
Which TILDRAKIZUMAB Alternatives Have Lower Condition aggravated Risk?
TILDRAKIZUMAB vs TILDRAKIZUMAB-ASMN
TILDRAKIZUMAB vs TILIDINE
TILDRAKIZUMAB vs TIMOLOL
TILDRAKIZUMAB vs TIMOLOL\TRAVOPROST
TILDRAKIZUMAB vs TINIDAZOLE